These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38049333)

  • 41. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
    Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
    Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
    Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
    Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study.
    Tun AM; Patel RD; St-Pierre F; Ouchveridze E; Niu A; Thordardottir T; Obasi J; Rosenthal A; Pophali PA; Fenske TS; Karmali R; Ahmed S; Johnston PB
    Am J Hematol; 2024 Sep; 99(9):1712-1720. PubMed ID: 38837403
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent remission of lymphoma and Sjögren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report.
    Sheng L; Zhang Y; Song Q; Jiang X; Cao W; Li L; Yi H; Weng X; Chen S; Wang Z; Wu W; Wang L; Zhao W; Yan Z
    Front Immunol; 2023; 14():1298815. PubMed ID: 38173731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.
    Ying Z; Xie Y; Zheng W; Liu W; Lin N; Tu M; Wang X; Ping L; Deng L; Zhang C; Wu M; Feng F; Du T; Tang Y; Su F; Guo Z; Li J; Song Y; Zhu J
    Bone Marrow Transplant; 2023 Mar; 58(3):288-294. PubMed ID: 36477110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
    Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
    Front Immunol; 2022; 13():969660. PubMed ID: 36059523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
    Roddie C; Dias J; O'Reilly MA; Abbasian M; Cadinanos-Garai A; Vispute K; Bosshard-Carter L; Mitsikakou M; Mehra V; Roddy H; Hartley JA; Spanswick V; Lowe H; Popova B; Clifton-Hadley L; Wheeler G; Olejnik J; Bloor A; Irvine D; Wood L; Marzolini MAV; Domning S; Farzaneh F; Lowdell MW; Linch DC; Pule MA; Peggs KS
    J Clin Oncol; 2021 Oct; 39(30):3352-3363. PubMed ID: 34464155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
    Dang X; Ye S; Zhou L; Lu Y; Li P; Liang A; Qian W
    Cytotherapy; 2023 Jun; 25(6):573-577. PubMed ID: 36456447
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma.
    Lei W; Zhao A; Liu H; Yang C; Wei C; Guo S; Chen Z; Guo Q; Li L; Zhao M; Wu G; Ouyang G; Liu M; Zhang J; Gao J; Qian W
    Cell Discov; 2024 Jan; 10(1):5. PubMed ID: 38191529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
    Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
    Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL.
    Song F; Hu Y; Zhang Y; Zhang M; Yang T; Wu W; Huang S; Xu H; Chang AH; Huang H; Wei G
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
    Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
    Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
    Tu S; Zhou X; Guo Z; Huang R; Yue C; He Y; Li M; Chen Y; Liu Y; Chang LJ; Li Y
    Front Oncol; 2019; 9():1350. PubMed ID: 31867275
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.